Epoch Biodesign 🇬🇧
Biorecycling with AI-designed enzymes that break down waste into recycled nylon 6,6.
About Epoch Biodesign
Epoch Biodesign specializes in biorecycling technologies that convert waste materials into recycled nylon 6,6, utilizing AI-designed enzymes to deconstruct materials at the molecular level. Their fully integrated supply chain supports the production of both conventional and biorecycled PA66, with plans for significant scaling in biorecycling capacity by 2029.
Epoch Biodesign is a UK-based company founded in 2019, now around 79 people. FundFinder classes it as AI & ML.
Founder: Jacob Nathan (Founder & CEO; American School In London).
Its investors also appear on FundFinder's most-active lists for Series A · Impact (27 funds), Series A · Fintech (84 funds), Series A · Climate & Sustainability (53 funds).
Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.
Series A · Mar 2026
- Extantia Capittal — Extantia Capital is a climate-first venture capital firm accelerating the path to a decarbonised world · cheques £2M – £10M
- Kompas VC — Kompas is an early-stage venture capital firm that invests on construction tech, prop tech, advanced materials, IoT, and climate tech. · cheques £700k – £10M